SKB378/WIN378 anti-TSLP antibody shows sustained lung function gains in Phase II. Advances to Phase III asthma trial with ...
Intellia Therapeutics receives FDA priority review for lonvo-z, a one-time CRISPR therapy for hereditary angioedema.
Inhibrx's INBRX-106 nearly doubles response rate versus Keytruda alone in head and neck cancer trial. See the breakthrough ...
Novo Nordisk halts Phase III ziltivekimab trials (HERMES, ATHENA) for heart failure after futility signal. Read the latest ...
FDA grants accelerated approval to Etcamah (camizestrant) for ESR1-mutated HR+ breast cancer. Learn about this new SERD ...
PDS Biotech secures $22.55M funding to advance PDS0301 immunotherapy into Phase III colorectal cancer trials. Read the latest ...
Helmholtz Munich and TUM researchers create AI-generated protein vehicles for RNA delivery that surpass lipid nanoparticles ...
Moonwalk Biosciences closes $70M Series B to advance adipose-targeted RNAi therapies for obesity and cardiometabolic diseases. Learn more about this ...
Novartis's pelacarsen misses primary endpoint in Phase III trial despite lowering Lp(a). Learn what this means for ...
Intellia Therapeutics secures $400M non-dilutive debt facility with OrbiMed to fund commercial launch of CRISPR gene therapy ...
Dimerix Limited secures AUD 34 million non-dilutive funding for Phase III FSGS trial. Discover how this funding advances ...
Superluminal Medicines secures $60M Series B funding to advance MC4R agonist into Phase I trials for rare genetic obesity.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results